{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["600(7)"],"submitter":["Southam K"],"pubmed_abstract":["Accurate modelling type 2 diabetes and diabetic complications in rodents has proven a challenge, largely as a result of the long-time course of disease development in humans. In the present study, we aimed to develop and comprehensively characterise a new rodent model of type 2 diabetes. To do this, we fed Sprague-Dawley rats a high fat/high sugar diet (HFD) to induce obesity and dyslipidaemia. After 3 weeks, we s.c. implanted osmotic mini pumps to enable a 14 day, slow infusion of streptozotocin (STZ; lower dose = 100 mg kg<sup>-1</sup> ; higher dose = 120 mg kg<sup>-1</sup> ) to dose-dependently reduce pancreatic beta cell mass. After removing the mini pumps, we monitored animals for 4 months using a battery of tests to assess both metabolic and neurodegenerative changes across time. Our"],"journal":["The Journal of physiology"],"pagination":["1611-1630"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9541365"],"repository":["biostudies-literature"],"pubmed_title":["Development and characterisation of a rat model that exhibits both metabolic dysfunction and neurodegeneration seen in type 2 diabetes."],"pmcid":["PMC9541365"],"pubmed_authors":["Southam K","de Sousa C","Premilovac D","Taylor BV","Daniel A","Foa L"],"additional_accession":[]},"is_claimable":false,"name":"Development and characterisation of a rat model that exhibits both metabolic dysfunction and neurodegeneration seen in type 2 diabetes.","description":"Accurate modelling type 2 diabetes and diabetic complications in rodents has proven a challenge, largely as a result of the long-time course of disease development in humans. In the present study, we aimed to develop and comprehensively characterise a new rodent model of type 2 diabetes. To do this, we fed Sprague-Dawley rats a high fat/high sugar diet (HFD) to induce obesity and dyslipidaemia. After 3 weeks, we s.c. implanted osmotic mini pumps to enable a 14 day, slow infusion of streptozotocin (STZ; lower dose = 100 mg kg<sup>-1</sup> ; higher dose = 120 mg kg<sup>-1</sup> ) to dose-dependently reduce pancreatic beta cell mass. After removing the mini pumps, we monitored animals for 4 months using a battery of tests to assess both metabolic and neurodegenerative changes across time. Our","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-05T20:11:47.059Z","creation":"2025-04-05T20:11:47.059Z"},"accession":"S-EPMC9541365","cross_references":{"pubmed":["35128667"],"doi":["10.1113/JP282454"]}}